These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24807558)

  • 1. CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.
    Gungor B; Yagci FC; Tincer G; Bayyurt B; Alpdundar E; Yildiz S; Ozcan M; Gursel I; Gursel M
    Sci Transl Med; 2014 May; 6(235):235ra61. PubMed ID: 24807558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
    Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
    Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.
    Kerkmann M; Rothenfusser S; Hornung V; Towarowski A; Wagner M; Sarris A; Giese T; Endres S; Hartmann G
    J Immunol; 2003 May; 170(9):4465-74. PubMed ID: 12707322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.
    Krug A; Rothenfusser S; Hornung V; Jahrsdörfer B; Blackwell S; Ballas ZK; Endres S; Krieg AM; Hartmann G
    Eur J Immunol; 2001 Jul; 31(7):2154-63. PubMed ID: 11449369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.
    Moseman EA; Liang X; Dawson AJ; Panoskaltsis-Mortari A; Krieg AM; Liu YJ; Blazar BR; Chen W
    J Immunol; 2004 Oct; 173(7):4433-42. PubMed ID: 15383574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of CpG ODN Based Vaccine Adjuvant Formulations.
    Gursel M; Gursel I
    Methods Mol Biol; 2016; 1404():289-298. PubMed ID: 27076306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs.
    Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Ojima T; Iida T; Hayata K; Yamaue H
    Int J Oncol; 2011 Nov; 39(5):1295-302. PubMed ID: 21805031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy.
    Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T
    Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNα secretion.
    Tel J; Beenhakker N; Koopman G; Hart B; Mudde GC; de Vries IJ
    Immunobiology; 2012 Oct; 217(10):1017-24. PubMed ID: 22349518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
    Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells.
    Gursel M; Verthelyi D; Klinman DM
    Eur J Immunol; 2002 Sep; 32(9):2617-22. PubMed ID: 12207346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.
    Oumouna M; Mapletoft JW; Karvonen BC; Babiuk LA; van Drunen Littel-van den Hurk S
    J Virol; 2005 Feb; 79(4):2024-32. PubMed ID: 15681404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
    Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
    Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.
    Gürsel M; Verthelyi D; Gürsel I; Ishii KJ; Klinman DM
    J Leukoc Biol; 2002 May; 71(5):813-20. PubMed ID: 11994506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
    Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
    Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha.
    Blackwell SE; Krieg AM
    J Immunol; 2003 Apr; 170(8):4061-8. PubMed ID: 12682235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
    Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
    Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
    Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
    Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.